Protein Terminal Analysis

Protein C-Terminal Sequencing Service

Confirm the C-terminal sequence of your protein by LC-MS/MS and carboxypeptidase laddering. Detect truncations, C-terminal lysine variants, amidation status, and post-translational modifications at the terminal residue with orthogonal validation.

LC-MS/MS Carboxypeptidase Laddering Variant Quantification Orthogonal Validation

Service Scope

C-terminal residue identification with variant detection down to <2% abundance

science

MS/MS

High-resolution LC-MS/MS for terminal peptide identification.

Laddering

CpY/CpB digestion for residue-by-residue confirmation.

Variants

Lys clipping, truncation, amidation detection & quantification.

Orthogonal

Two independent methods for terminal confirmation.

<2%

Low-abundance variant detection limit.

≥99%

Terminal localization confidence.

Dual

MS/MS + laddering for confirmation.

Service Details

Workflow

Platform

Applications

Deliverables

Case Study

Request a Quote

What Is Protein C-Terminal Sequencing?

The C-terminal sequencing, plays a decisive role in the biological function of proteins, is an important structural and functional part of proteins and polypeptides. In addition, C-terminal modification is also one of the important post-translational modifications of proteins. The current protein sequencing methods mainly include carboxypeptidase method, chemical methods, and tandem mass spectrometry, of which MS/MS has been used to sequence peptides and small proteins for a number of years.

This method allows one to isolate the peptide of interest, which makes it possible to analyze impure samples and unseparated mixtures, such as protein digests. Collision-induced dissociation (CID) of the selected peptide generates product ions that provide sequence information from which the C-terminal residue can be unambiguously identified.

Creative Proteomics relies on the company's existing mass spectrometry platform to develop a powerful LC-MS/MS system for C-terminal sequence determination, with carboxypeptidase laddering as an orthogonal confirmation method to ensure terminal assignment accuracy.

Scientific illustration showing C-terminal sequencing workflow — protein with highlighted C-terminus, carboxypeptidase digestion generating a mass ladder, and MS/MS spectrum confirming the terminal residue.

C-Terminal Sequencing Methods

Method	Principle	Sample Requirement	Key Advantage	Key Limitation
LC-MS/MS (Primary)	Enzymatic digestion → terminal peptide isolation → CID/HCD fragmentation → b/y ion series assignment	≥5–10 µg protein; moderate purity acceptable	Mixture-compatible; simultaneous N- and C-terminal detection; detects modifications (amidation, truncation, PTMs)	Terminal peptide must ionize; may require multiple proteases for complete coverage
Carboxypeptidase Laddering	CpY/CpB sequentially removes C-terminal residues; time-resolved MS detects mass ladder with stepwise mass shifts	≥20–50 µg purified protein; intact protein required	Residue-by-residue confirmation; orthogonal to MS/MS; no protein digestion required	Cannot penetrate blocked C-termini; requires high-purity protein sample
Chemical Cleavage	Chemical reagents selectively cleave near C-terminus; released fragment analyzed by MS	≥50 µg; specialized buffer conditions required	Accessible when enzymatic methods fail; works on some blocked C-termini	Low specificity; side reactions common; largely superseded by MS/MS methods

Our C-Terminal Sequencing Services

LC-MS/MS-based C-terminal sequence determination with carboxypeptidase laddering for orthogonal confirmation. Each analysis targets the terminal peptide and reports variant populations with quantitative abundance.

verified

C-Terminal Residue Verification

Confirm the identity of the final amino acid residue in your protein or peptide. Essential for verifying complete expression of recombinant proteins and confirming that no unexpected C-terminal truncation has occurred during expression or purification. Simultaneous determination of N-terminal and C-terminal sequences in one experiment.

LC-MS/MS CID/HCD

donut_small

C-Terminal Variant Detection

Detect and quantify C-terminal heterogeneity — lysine clipping (Lys⁺/Lys⁻), glycine loss, amidation, and truncation variants. Critical for monoclonal antibody characterization and recombinant protein QC with detection below 2% relative abundance.

Variant Quantification

edit_note

C-Terminal Modification Analysis

Determine the chemical state of the C-terminus — free carboxyl (–COOH), amidated (–CONH₂), or esterified. Distinguish post-translational modifications at the terminal residue that affect bioactivity, stability, and lot comparability.

PTM Focus

find_in_page

Neo-C-Termini Discovery

Identify protease-generated neo-C-termini in complex biological samples. Map cleavage sites, characterize protease specificity, and track degradation products — applicable to protease characterization and stability studies at proteome scale.

Discovery

How C-Terminal Sequencing Works

A dual-method approach combining LC-MS/MS terminal peptide identification with carboxypeptidase laddering for orthogonal confirmation.

Project Scoping

Define study objectives — terminal verification, variant quantification, or neo-termini discovery. Identify expected C-terminal features and select the appropriate analytical strategy.

Sample Preparation

Assess sample purity and buffer composition. Perform reduction and alkylation if disulfide bonds are present. For MS/MS: enzymatic digestion (trypsin, Glu-C, etc.). For laddering: direct CpY/CpB timed digestion.

MS Acquisition

High-resolution LC-MS/MS with data-dependent acquisition (DDA) for terminal peptide identification. For laddering: time-point sampling followed by intact mass measurement to track sequential residue loss.

Data Processing

Terminal-aware database search with localization scoring. b/y ion series confirmation of C-terminal residue assignment. Ladder data analyzed for stepwise mass shifts matching sequential amino acid loss.

Orthogonal Validation

MS/MS and laddering results are cross-validated. Only terminal assignments confirmed by both independent methods are reported. Any discrepancies trigger re-analysis or method adjustment.

Technology Platform for C-Terminal Sequencing

Close-up of UHPLC and Orbitrap mass spectrometer instrumentation used for high-resolution protein C-terminal sequencing analysis.

biotech

Orbitrap / Q-Exactive LC-MS/MS Platform

High-resolution tandem mass spectrometry with ≤3 ppm mass accuracy supports confident terminal peptide identification. HCD and ETD fragmentation modes provide complementary ion series for terminal assignment.

timeline

Carboxypeptidase Laddering Strategy

CpY and CpB enzymatic digestion generates time-resolved mass ladders for residue-by-residue C-terminal confirmation. This orthogonal approach validates MS/MS assignments and catches single-method errors.

terminal

Terminal-Aware Database Search

Standard peptide mapping searches assume tryptic cleavage at expected sites — missing terminal truncations. Our terminal-aware search parameters allow non-specific cleavage at the C-terminus, capturing low-abundance variants that routine analyses overlook.

psychology

Expert Manual Data Review

Every terminal assignment is manually inspected by an experienced mass spectrometrist. Low-abundance variant signals are reviewed against noise thresholds — automated software alone cannot reliably distinguish true variants from background at detection limits below 2%.

Applications of C-Terminal Sequencing

C-terminal sequencing supports protein characterization, biopharmaceutical QC, and protease research across multiple application areas.

medication

Monoclonal Antibody QC

Quantify C-terminal lysine clipping (0K/1K/2K) — one of the most common charge variants in mAb production. Detect novel truncations such as des-GK that standard peptide mapping may miss.

biotech

Recombinant Protein Verification

Confirm full-length expression without C-terminal truncation. Verify the translation termination site matches expectations across expression systems (E. coli, CHO, HEK293).

integration_instructions

Peptide API & Fusion Protein QC

Distinguish –COOH vs –CONH₂ vs esterified termini. Confirm His-tag, linker, or payload integrity at the C-terminus of engineered proteins and therapeutic peptides.

cut

Protease Specificity Profiling

Map cleavage sites at residue resolution. Generate sequence motif logos for protease cleavage preferences and track degradation products under stress or storage conditions.

sync_alt

Biosimilar Comparability

Compare C-terminal variant profiles between innovator and biosimilar products. Quantify differences in lysine clipping, truncation, and terminal modification patterns.

monitoring

Stability & Degradation Studies

Track C-terminal degradation or truncation under thermal, oxidative, or pH stress. Support formulation development and forced degradation studies with quantitative variant profiling.

Advantages of Creative Proteomics C-Terminal Sequencing

Creative Proteomics provides C-terminal sequencing solutions with orthogonal validation and expert data review for confident terminal residue identification.

check_circle

Dual-Method Orthogonal Validation

Every terminal assignment is confirmed by two independent methods — LC-MS/MS fragmentation and carboxypeptidase laddering — providing the highest confidence in terminal residue identification.

bar_chart

Low-Abundance Variant Detection

PRM/MRM-based targeted quantification detects C-terminal variants below 2% relative abundance. Expert manual review distinguishes true variants from chemical noise at trace levels.

sync

N- and C-Terminal Simultaneously

The same LC-MS/MS experiment identifies both terminal peptides — providing complete terminal characterization in a single analysis with reduced sample consumption.

terminal

Terminal-Aware Search Strategy

Database search parameters allow non-specific cleavage at the C-terminus, capturing truncated variants that standard trypsin-only searches miss — the same approach that detected the des-GK truncation variant.

edit_note

Modification-State Differentiation

Distinguish free carboxyl, amidated, and esterified C-termini by MS/MS with modification-aware database search and targeted PRM transitions.

description

Transparent Data Reporting

Every terminal assignment is supported by annotated MS/MS spectra, laddering time-point data, variant quantification tables, and localization scores — no black-box results.

Sample Requirements for C-Terminal Sequencing

Sample requirements vary depending on protein type, workflow, and project objective. The table below provides general guidance — final requirements should be confirmed during project evaluation.

Sample Type	Minimum Amount	Purity	Buffer Compatibility	Notes
Purified Proteins (mAbs, enzymes)	≥20–50 µg	≥90%	Volatile buffers preferred; salt ≤50 mM	Avoid high glycerol or SDS; indicate disulfide status
Synthetic Peptides / Peptide APIs	≥5–10 µg	≥95%	Water, 0.1% formic acid, or mild buffers	Specify expected C-terminal modifications (amidation, ester)
Gel Bands / Gel Spots	Visible Coomassie-stained band	Single band preferred	N/A (excise with clean tools)	Avoid excessive handling; ship in Eppendorf tube
Liquid Samples	≥5–10 µg total protein	As high as possible	Note buffer composition at submission	Provide estimated total protein concentration
Cell Lysates / Complex Matrices	≥100–300 µg total protein	Enrichment recommended	Urea ≤1 M; SDS <0.03% after cleanup	Provide lysis buffer details; reduction/alkylation may be required

What You Receive

Comprehensive C-terminal sequencing deliverables with raw data, processed results, and expert interpretation.

analytics

Annotated MS/MS Spectra

Annotated fragmentation spectra of the C-terminal peptide with b/y ion series labeled. Each spectrum supports the terminal residue assignment.

table_chart

Variant Quantification Tables

Quantitative abundance table for each detected C-terminal variant with relative percentages and localization confidence scores.

description

Executive Summary

Methods description, terminal assignment summary, variant quantification overview — structured for inclusion in characterization reports.

folder_open

Raw Data Files

All raw MS data files, laddering time-point data (when applicable), and processed search results for independent verification.

For complementary protein characterization services — including N-terminal sequencing (determined simultaneously from the same LC-MS/MS experiment), peptide mapping for full-sequence confirmation, and peptide testing for synthetic peptide QC — contact our team to discuss your project requirements.

Open analytical report booklet showing C-terminal sequencing results — annotated MS/MS spectrum with b/y ions, variant quantification table, and laddering time-point mass data.

Published Research

Detection of Heavy-Chain C-Terminal Des-GK Truncation in a Monoclonal Antibody

Journal

J Pharm Sci

Year

2023

DOI

10.1016/j.xphs.2023.05.014

Study Overview

Faulkner et al. (Journal of Pharmaceutical Sciences, 2023) identified a previously unreported heavy-chain C-terminal variant — des-GK truncation — in a recombinant monoclonal antibody. The variant involves loss of the terminal glycine-lysine dipeptide from the heavy chain, producing a C-terminus ending in proline rather than the expected glycine. This truncation was present at low abundance (<5%) and had gone undetected by routine intact mass and peptide mapping analyses, which lacked the terminal-specific search parameters needed to identify the missing residues.

Key Methods

Intact mass analysis — detected an unexpected mass shift of −185 Da in a minor heavy-chain population
Peptide mapping with terminal-specific search — database search configured to allow non-specific cleavage at the C-terminus
MS/MS fragmentation — b/y ion series confirmed the terminal proline residue of the des-GK variant
Carboxypeptidase B digestion — confirmed absence of the C-terminal lysine in the truncated population

Relevance to C-Terminal Sequencing

Demonstrates that standard peptide mapping workflows — which assume complete tryptic digestion — can miss C-terminal truncations if terminal-nonspecific searches are not performed.
Highlights why dedicated C-terminal sequencing with terminal-focused search parameters is necessary for complete protein characterization.
Shows the value of orthogonal confirmation: intact mass flagged the anomaly, MS/MS localized it, and CpB digestion confirmed the finding.

Key Finding

A novel C-terminal truncation — loss of the terminal glycine-lysine dipeptide — was detected at low abundance in a recombinant monoclonal antibody. The variant had evaded detection by routine analytical methods because standard peptide mapping database searches assume tryptic cleavage at the expected C-terminal lysine. This case illustrates a fundamental blind spot in conventional protein characterization: without C-terminal-specific search strategies, low-abundance terminal truncations can persist undetected through release testing, stability studies, and comparability assessments.

Publication Reference

Faulkner S, Elia N, O'Hara D, Dunn Z, Kwok S. Observation of Heavy-Chain C-Terminal Des-GK Truncation in a Recombinant Monoclonal Antibody. J Pharm Sci. 2023;112(7):1845–1852. DOI: 10.1016/j.xphs.2023.05.014.

Frequently Asked Questions

How is C-terminal sequencing different from N-terminal sequencing?expand_more

N-terminal sequencing (Edman degradation) is a well-established chemical method that sequentially removes and identifies amino acids from the N-terminus. C-terminal sequencing has no equivalent chemical method with comparable efficiency — instead, it relies on mass spectrometry (LC-MS/MS) and enzymatic laddering (carboxypeptidase digestion). In practice, our LC-MS/MS approach determines both N- and C-terminal sequences simultaneously from the same experiment.

What is C-terminal lysine clipping and why does it matter?expand_more

C-terminal lysine clipping is the partial removal of the heavy-chain C-terminal lysine residue during monoclonal antibody production. A single mAb sample typically contains a mixture of species with 0, 1, or 2 C-terminal lysines (0K/1K/2K). Since lysine is positively charged, the ratio directly affects charge heterogeneity — a critical quality attribute for mAb characterization and biosimilar comparability.

Can you sequence blocked or modified C-termini?expand_more

Yes. We can identify amidated (–CONH₂), esterified, and truncated C-termini by LC-MS/MS with modification-aware database search parameters. Carboxypeptidase digestion may be impaired if the terminal residue carries a modification that blocks enzyme access — in such cases, MS/MS is the primary identification method.

What sample purity is required for C-terminal sequencing?expand_more

For terminal verification of purified proteins, ≥90% purity is recommended — higher purity yields cleaner spectra and higher-confidence assignments. However, MS/MS-based C-terminal sequencing can work with moderately impure samples because the peptide of interest is isolated by mass selection before fragmentation. For complex mixtures, enrichment strategies can be applied before analysis.

How do you confirm the terminal assignment is correct and not an internal fragment?expand_more

We use terminal-diagnostic ion series in MS/MS spectra — b and y ions that specifically indicate the peptide terminus. Assignments are filtered by localization scoring and FDR control. For critical applications, carboxypeptidase laddering provides an orthogonal confirmation: if the same residue sequence is observed by both MS/MS fragmentation and sequential enzymatic removal, confidence in the terminal assignment is extremely high.